Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | CAD | P27708 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783557 | 0.81 | NAAA (0.40) | MGAMGAASIMGAM2 | |
| SCHEMBL1853831 | 0.78 | L3MBTL1 (0.33) | L3MBTL1KMT2APOLBMGAMGAA | |
| SCHEMBL6276297 | 0.71 | MGAM (0.46) | MGAMGAASIMGAM2 | |
| SCHEMBL3623524 | 0.69 | GAA (0.38) | MGAMGAASIMGAM2 | |
| SCHEMBL12514827 | 0.69 | ALDH1A1 (0.35) | GAA | |
| SCHEMBL13628930 | 0.68 | CYP2C9 (0.38) | L3MBTL1KMT2APOLB | |
| SCHEMBL18354703 | 0.68 | CYP1A2 (0.60) | L3MBTL1GAA | |
| SCHEMBL1849412 | 0.68 | — | — | |
| SCHEMBL11720069 | 0.67 | TSHR (0.43) | KMT2A | |
| SCHEMBL783993 | 0.66 | ALDH1A1 (0.46) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2324041-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | L3MBTL1 2345/4885KMT2A 4393/4885POLB 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.